Open an account

Procept Biorobotics

PRCT · NASDAQ

$18.82+$0.54 (+2.95%)TodayMarket closed ·
Prev close $18.28

About PRCT

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. The company is headquartered in San Jose, California and currently employs 888 full-time employees. The company went IPO on 2021-09-15. The firm is focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The firm's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.

Employees
888
Headquarters
San Jose, California
Listed
Sep 15, 2021
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
procept-biorobotics.com

PRCT key statistics

Market cap
1.08B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.38M
Volume
985.60K
Open price
$18.32
High today
$19.11
Low today
$18.22
52 Week high
$38.11
52 Week low
$16.67

Procept Biorobotics (PRCT) at a glance

Procept Biorobotics (PRCT) last traded at $18.82, with a market cap of 1.08B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $18.22 and $19.11. The current price is 3.3% above the day's low and 1.5% below its high.

Volume so far is 985.60K shares, below the average of 1.38M shares a day.

Over the past year Procept Biorobotics has ranged from $16.67 to $38.11, and now sits 10% of the way up that range.

Procept Biorobotics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.47 per share against an estimate of -$0.4661.

The average analyst price target is $24.72, 31.3% above the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

46%of 13 analyst ratings say Buy
  • Buy46.2%
  • Hold46.2%
  • Sell7.7%
Price target · 15 analystsAvg $24.72
Low
$16.16
Now
$18.82
High
$53.55

PRCT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 11.6% on average.

  1. Q3 FY24: reported -$0.40 per share against an estimate of -$0.4983
  2. Q4 FY24: reported -$0.35 per share against an estimate of -$0.3343
  3. Q1 FY25: reported -$0.45 per share against an estimate of -$0.4998
  4. Q2 FY25: reported -$0.35 per share against an estimate of -$0.4231
  5. Q3 FY25: reported -$0.38 per share against an estimate of -$0.4198
  6. Q4 FY25: reported -$0.53 per share against an estimate of -$0.3307
  7. Q1 FY26: reported -$0.56 per share against an estimate of -$0.5676
  8. Q2 FY26: reported -$0.47 per share against an estimate of -$0.4661

PRCT news

  • Press releasePRNewswire

    PROCEPT BioRobotics (NASDAQ: PRCT) Investors: Securities Class Action Filed; Shareholders Should Contact Shareholders Foundation

  • Press releaseGlobe Newswire

    LAWSUIT ALERT: Investors who lost money with PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares should contact the Shareholders Foundation

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PROCEPT BioRobotics Corporation of Class Action Lawsuit and Upcoming Deadlines – PRCT

  • Press releaseGlobe Newswire

    Portnoy Law Firm Announces Class Action on Behalf of PROCEPT BioRobotics Corporation Investors

  • Press releaseGlobe Newswire

    Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigating Claims on Your Behalf

  • Press releasePRNewswire

    PROCEPT BioRobotics Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PRCT

  • Press releasePRNewswire

    PRCT Deadline: PRCT Investors with Losses in Excess of $100K Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit

  • Press releaseGlobe Newswire

    Deadline Alert: PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Similar companies

Companies in the same industry as Procept Biorobotics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.